Stable Virologic Suppression during Raltegravir plus Atazanavir Dual-Therapy Taken Every other Day: A Case Report
Elisa Gentilotti*, Pasquale De Nardo, Angela Corpolongo, Massimo Tempestilli, Alessandra Oliva, R ita Bellagamba, Chiara Tommasi, Nicola Tumino, Pasquale Narciso and Emanuele Nicastri
Department of Tropical Medicine and Infectious Diseases, “L. Spallanzani” National Institute for Infectious Diseases IRCCS, via Portuense 292, 00149 Rome, Italy
- *Corresponding Author:
- Elisa Gentilotti
“L. Spallanzani”, National Institute for Infectious Diseases IRCCS
via Portuense 292, 00149 Rome, Italy
E-mail: [email protected]
Received Date: April 28, 2012; Accepted Date: July 18, 2012; Published Date: July 22, 2012
Citation: Gentilotti E, De Nardo P, Corpolongo A, Tempestilli M, Oliva A, et al. (2012) Stable Virologic Suppression during Raltegravir plus Atazanavir Dual-Therapy Taken Every other Day: A Case Report. J AIDS Clinic Res S2:006. doi:10.4172/2155-6113.S2-006
Copyright: © 2012 Gentilotti E, et al. This is an open-access article distributedunder the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Adherence to Highly Active Antiretroviral Therapy can be affected by a number of factors limiting the outcome of the treatment. We report the case of a 39 year-old HIV-HCV co-infected woman in stable virologic suppression and immune recovery during a raltegravir plus unboosted atazanavir dual-therapy taken every other day. Measurement of HIV-1 RNA plasma levels (viral load), CD4+ T-cell counts and the therapeutic drug monitoring through validated high-performance liquid chromatography methods, were performed to assess the effectiveness of this regimen. Our data on raltegravir pharmacokinetics in association with atazanavir show adequate minimum effective concentrations of raltegravir throughout 36 and 48 hours despite the every other day intake of the drug. Further studies are recommended in order to identify the determinants that could enable a reduction in antiretroviral dosing frequency in case of difficult management of HIV-infected patients due to low adherence to therapy. By reporting our medical experience, we focused on the utility of performing therapeutic drug monitoring especially in cases of poor adherence, drug and/or alcohol abuse, co morbidities and co-administration of other drugs.